Cancer Genetics, Inc. to Present at American Society of Hematology (ASH) Annual Meeting

- Cancer Genetics will present two posters on diffuse large B-cell lymphoma (DLBCL), the most common form of B-cell cancers.
- OncoSpire Genomics, Cancer Genetics' joint venture with Mayo Clinic, to present on proprietary NGS-based panel for multiple myeloma (MM).

RUTHERFORD, N.J., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the Company"), an emerging leader in DNA-based cancer diagnostics, announced today that it will present two posters on diffuse large B-cell lymphoma (DLBCL) at the 56th annual meeting of the American Society of Hematology (ASH), in San Francisco, CA. A third poster on multiple myeloma (MM) will be presented by OncoSpire Genomics, CGI's joint venture with Mayo Clinic.

The first poster, "Robust Assessment of Genomic Imbalance in Diffuse Large B-Cell Lymphoma Confirms Inferior Outcome Is Associated with Genomic Complexity and Identifies Potential Therapeutic Pathway Targets" (abstract 71186) will be presented Sunday, December 7 at 6:00 pm and will report the results of an investigation which correlated genomic complexity with outcome in DLBCL patients previously treated with RCHOP – the current frontline treatment for the disease. In addition to confirming that genomic complexity is associated with poorer survival in DLBCL patients, the study identified biological pathways in DLBCL that may represent potential therapeutic targets.

Cancer Genetics' second poster, "Genomic Complexity in Diffuse Large B-Cell Lymphoma is Associated with p53 Expression and Inferior Survival" (abstract 74868) will report results from a collaboration with the University of Southern California’s Keck School of Medicine on Sunday, December 7, 2014 at 6:00 pm in the Moscone Center, West Building. The study found that expression of a specific biomarker (p53) was associated with underlying genomic complexity, and therefore poor prognosis. Investigators also found that loss of the TP53 locus marked another subset of DLBCL patients with poor survival independent of p53 expression.

DLBCL is the most common type of aggressive non-Hodgkin Lymphoma, accounting for approximately 40% of all B-cell malignancies. An estimated 190,000 people in the United State are currently living with or are in remission from DLBCL, and approximately 20,000 new cases are diagnosed each year.

Despite excellent initial responses of DLBCL patients to current frontline immunotherapy (R-CHOP), only about 40% of patients are ultimately cured, with most relapses occurring within the first two to three years.

"Integrating the findings from examination of the DLBCL genome via profiling technologies with other biomarkers – such as those generated by immunohistochemistry – will increasingly be implemented in the routine diagnostic setting, and will enhance the overall role of diagnostics in the clinical management of DLBCL patients," said Jane Houldsworth, Ph.D., vice president of research and development at CGI.

OncoSpire Genomics, the Company's joint-venture with Mayo Clinic, will deliver an oral presentation showcasing the joint-venture's proprietary NGS-based panel for multiple myeloma. "Development and Results of a Multiple Myeloma Specific Custom 77-Gene Mutation Panel for Clinical Targeted Sequencing" will be presented Sunday, December 7, 2014 at 4:30 pm.

About 24,000 new cases of multiple myeloma are diagnosed in the US each year. While a number of tests are currently used to diagnose MM, there remains significant need for more precise genomic tests to help diagnose, prognose, and guide treatment selection for this disease.

Representatives from Cancer Genetics will also be exhibiting at the conference at booth # 431.

About Cancer Genetics

Cancer Genetics Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict
treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference labs are focused entirely on maintaining clinical excellence and are both CLIA certified and CAP accredited and have licensure from several states including New York State.

We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.

For more information, please visit or follow us:

- Internet: [www.cancergenetics.com](http://www.cancergenetics.com)
- Twitter: [@Cancer_Genetics](https://twitter.com/Cancer_Genetics)
- Facebook: [www.facebook.com/CancerGenetics](http://www.facebook.com/CancerGenetics)

Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that the transaction will not close or, if it closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended September 30, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

CONTACT: Investor Relations
Andrew McDonald Ph.D.
Life Science Advisors LLC
646-597-6987

Media Relations
Paul Kuntz
RedChip Companies, Inc.
800-733-2447, ext. 105
paul@redchip.com

Source: Cancer Genetics